Korean J Med.  2017 Apr;92(2):142-149. 10.3904/kjm.2017.92.2.142.

Glucocorticoid-induced Osteoporosis

• Jung JY
• Suh CH

• KMID: 2382653
• DOI: http://doi.org/10.3904/kjm.2017.92.2.142

Abstract

Osteoporosis is a common adverse event among patients on glucocorticoid therapy. Glucocorticoids reduce bone formation and increase cortical porosity in proportion to the dose and duration of glucocorticoid use. While the epidemiology of glucocorticoid-induced osteoporosis has been well characterized, its pathophysiology and effective management remain unclear. Several recommendations for glucocorticoid-induced osteoporosis are used to determine which patients on long-term glucocorticoid treatment to treat and when. The fracture risk can be assessed using dual-energy X-ray absorptiometry and the Fracture Risk Assessment Tool algorithm, along with other clinical factors. The management of glucocorticoid-induced osteoporosis includes anti-osteoporotic therapy and measures to prevent bone loss. Bisphosphonates are currently the first choice treatment, with teriparatide and denosumab being alternatives.

Keyword

Glucocorticoid; Osteoporosis; Bone mineral density

MeSH Terms

Absorptiometry, Photon
Bone Density
Denosumab
Diphosphonates
Epidemiology
Glucocorticoids
Humans
Osteogenesis
Osteoporosis*
Porosity
Risk Assessment
Teriparatide
Denosumab
Diphosphonates
Glucocorticoids
Teriparatide